Founded in 2012 and headquartered in Buffalo, New York, MimiVax is a privately-held, clinical-stage biotechnology company dedicated to developing and commercializing immunotherapeutic vaccines and targeted therapies for cancer treatment. The company's core mission is to disrupt cancer by improving survival rates and providing hope to patients. MimiVax's flagship product, SurVaxM, targets the survivin protein, which is present in most cancers, aiming to enhance the efficacy of existing treatments and offer new therapeutic options.
MimiVax has garnered attention through its innovative approach and notable affiliations with leading researchers and institutions. The company's key achievements include advancing SurVaxM through clinical trials, demonstrating promising results in Phase IIa studies for newly diagnosed glioblastoma. With significant backing from investors and a committed leadership team, MimiVax continues to make impactful strides in the oncology field, aiming to transform cancer treatment paradigms and improve patient outcomes globally.
